Benda Pharmaceutical: Plans to issue H shares and list on the main board of the Hong Kong Stock Exchange

Beijing Tide Pharmaceutical announced that in order to enhance its capital strength and comprehensive competitiveness, and to further promote its internationalization process, the company plans to issue overseas listed shares and apply for listing on the main board of the Hong Kong Stock Exchange. The company will fully consider the interests of existing shareholders and the conditions of domestic and foreign capital markets, and will choose an appropriate timing and issuance window to complete this issuance and listing within the validity period of the shareholders' meeting resolution. Currently, the company is discussing relevant work for this issuance and listing with related intermediary institutions, and specific details have not yet been finalized. This issuance and listing still needs to be submitted for review by the company's shareholders' meeting and must obtain the filing, approval, and/or authorization from relevant government agencies, regulatory bodies, and stock exchanges such as the China Securities Regulatory Commission and the Hong Kong Stock Exchange